Your browser doesn't support javascript.
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Yeoh, Su-Ann; Gianfrancesco, Milena; Lawson-Tovey, Saskia; Hyrich, Kimme L; Strangfeld, Anja; Gossec, Laure; Carmona, Loreto; Mateus, Elsa F; Schäfer, Martin; Richez, Christophe; Hachulla, Eric; Holmqvist, Marie; Scirè, Carlo Alberto; Lorenz, Hanns-Martin; Voll, Reinhard E; Hasseli, Rebecca; Jayatilleke, Arundathi; Hsu, Tiffany Y-T; D'Silva, Kristin M; Pimentel-Quiroz, Victor R; Vasquez Del Mercado, Monica; Shinjo, Samuel Katsuyuki; Neto, Edgard Torres Dos Reis; Junior, Laurindo Ferreira da Rocha; de Oliveira E Silva Montandon, Ana Carolina; Pons-Estel, Guillermo J; Ornella, Sofía; D'Angelo Exeni, Maria Eugenia; Velozo, Edson; Jordan, Paula; Sirotich, Emily; Hausmann, Jonathan S; Liew, Jean W; Jacobsohn, Lindsay; Gore-Massy, Monique; Sufka, Paul; Grainger, Rebecca; Bhana, Suleman; Wallace, Zachary; Robinson, Philip C; Yazdany, Jinoos; Machado, Pedro M.
  • Yeoh SA; Centre for Rheumatology, University College London, London, UK.
  • Gianfrancesco M; Department of Rheumatology, University College London University Hospitals NHS Foundation Trust, London, UK.
  • Lawson-Tovey S; Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Hyrich KL; Centre for Genetics and Genomics Versus Arthritis, University of Manchester, Manchester, UK.
  • Strangfeld A; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.
  • Gossec L; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.
  • Carmona L; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
  • Mateus EF; German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Services Research, Berlin, Germany.
  • Schäfer M; Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France.
  • Richez C; Department of Rheumatology, APHP, Pitié-Salpêtrière Hospital, Paris, France.
  • Hachulla E; Instituto de Salud Musculoesquelética (INMUSC), Madrid, Spain.
  • Holmqvist M; Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.
  • Scirè CA; German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Services Research, Berlin, Germany.
  • Lorenz HM; Département de Rhumatologie, Referral Center for Rare Systemic Autoimmune Diseases RESO, CHU de Bordeaux, Bordeaux, France.
  • Voll RE; UMR CNRS 5164, Université de Bordeaux, Bordeaux, France.
  • Hasseli R; Lille Inflammation Research International Center (LIRIC), University of Lille, Lille, France.
  • Jayatilleke A; Département de Médecine Interne et Immunologie Clinique, Referral Center for Rare Systemic Autoimmune Diseases North and Northwest of France (CeRAINO), INSERM U995, CHU Lille, Lille, France.
  • Hsu TY; Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden.
  • D'Silva KM; Epidemiology Unit, Italian Society for Rheumatology (SIR), Milan, Italy.
  • Pimentel-Quiroz VR; Division of Rheumatology, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany.
  • Vasquez Del Mercado M; Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs University of Freiburg, Freiburg, Germany.
  • Shinjo SK; Department of Internal Medicine II, University Hospitals Giessen, Justus-Liebig-University Giessen, Giessen, Germany.
  • Neto ETDR; Section of Rheumatology, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Junior LFDR; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • de Oliveira E Silva Montandon AC; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
  • Pons-Estel GJ; Department of Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.
  • Ornella S; Universidad Cientifica del Sur, Lima, Peru.
  • D'Angelo Exeni ME; University of Guadalajara, Guadalajara, Mexico.
  • Velozo E; Division of Rheumatology, Faculdade de Medicina (FMUSP), Universidade de São Paulo, São Paulo, Brazil.
  • Jordan P; Division of Rheumatology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
  • Sirotich E; Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Recife, Brazil.
  • Hausmann JS; Hospital das Clínicas, Universidade Federal de Goias (UFG), Goiania, Brazil.
  • Liew JW; Argentine Society of Rheumatology, Buenos Aires, Argentina.
  • Jacobsohn L; Hospital Interzonal General de Agudos (HIGA) San Martin, La Plata, Buenos Aires, Argentina.
  • Gore-Massy M; Sanatorio Parque, Córdoba, Argentina.
  • Sufka P; Sanatorio y Universidad Adventista del Plata, Libertador San Martín, Entre Ríos, Argentina.
  • Grainger R; Myositis UK, Southampton, UK.
  • Bhana S; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Wallace Z; Canadian Arthritis Patient Alliance, Toronto, ON, Canada.
  • Robinson PC; Program in Rheumatology, Boston Children's Hospital, Boston, MA, USA.
  • Yazdany J; Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Machado PM; Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
RMD Open ; 8(2)2022 09.
Article in English | MEDLINE | ID: covidwho-2029523
ABSTRACT

OBJECTIVES:

To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).

METHODS:

Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.

RESULTS:

Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).

CONCLUSIONS:

This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Physicians / Rheumatology / COVID-19 / Myositis Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Year: 2022 Document Type: Article Affiliation country: Rmdopen-2022-002508

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Physicians / Rheumatology / COVID-19 / Myositis Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Year: 2022 Document Type: Article Affiliation country: Rmdopen-2022-002508